| Trial ID # | NCT02799095; ARTISTRY-1 |
| Phase | I/II |
| Drug Class | Immunotherapy: Checkpoint Inhibitors/PD-1 |
| Drug Name | Pembrolizumab |
| Alternate Drug Names | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 |
| Drugs in Trial | Nemvaleukin alfa, Pembrolizumab |
| Eligible Participant | Advanced solid tumors |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, DoR, evaluated per RECIST |
| Efficacy | ALKS 4230: 36 patients, median 3 prior therapies (1-8), 1 ovarian ALKS 4230+Pem: 14 ovarian, median 5 prior therapies (2-11) |
| Conclusion | Pembrolizumab with Nemvaleukin alfa (ALKS 4230) is well tolerated with encouraging clinical benefit |
| Reference | Boni V et al. ARTISTRY-1: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors. J Clin Oncol (2021) 39 (suppl 15; abstr 2513) Boni V et al. Poster Slide from SGO 2022 presentation; scientific plenary III, abstract 229 Vaishampayan UN et al. Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1. J Clin Oncol 40, 2022 (suppl 16; abstr 2500) Vaishampayan UN et al. Slide from presentation |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.